The extracellular matrix in asthmatic lungs contains abundant low-molecular-weight
hyaluronan, and this is known to promote antigen presentation and allergic responses. Conversely, high-molecular-weight
hyaluronan (HMW-HA), typical of uninflamed tissues, is known to suppress
inflammation. We investigated whether HMW-HA can be adapted to promote tolerance to airway
allergens. HMW-HA was thiolated to prevent its catabolism and was tethered to
allergens via
thiol linkages. This platform, which we call "XHA," delivers antigenic payloads in the context of antiinflammatory costimulation.
Allergen/XHA was administered intranasally to mice that had been sensitized previously to these
allergens. XHA prevents allergic airway
inflammation in mice sensitized previously to either
ovalbumin or cockroach
proteins.
Allergen/XHA treatment reduced inflammatory cell counts,
airway hyperresponsiveness,
allergen-specific
IgE, and T helper type 2 cell
cytokine production in comparison with
allergen alone. These effects were
allergen specific and
IL-10 dependent. They were durable for weeks after the last challenge, providing a substantial advantage over the current desensitization protocols. Mechanistically, XHA promoted CD44-dependent inhibition of nuclear factor-κB signaling, diminished dendritic cell maturation, and reduced the induction of
allergen-specific CD4 T-helper responses. XHA and other potential strategies that target CD44 are promising alternatives for the treatment of
asthma and allergic
sinusitis.